+1.925.223.6233

In fact, Overall, Choosing a dependable online casino demands calm judgement, because the conditions shape the experience much more bold slogans. Keep in mind that To get a practical starting point, many readers frequently look at blik online casino, assuming they study the details carefully. Also, Welcome offers look tempting, yet their real value rests on the wagering terms, which deserve a close look. Banking methods need to be convenient, and the withdrawal speed is usually one of the most telling signs of a fair brand. Also, The range of titles tends to be broad, from video slots to roulette, giving players real choice. Also, Live dealer play appeals to players with real-time streams, and the stream quality shape the whole atmosphere. Also, A responsive help desk makes the difference whenever questions arise, especially if live chat are on hand. Also, Payouts reveal the true character behind a casino, so clear limits and quick processing build confidence. Also, Sensible gaming should stay central, so reality checks and clear budgets truly protect the user. Moreover, Besides, A proper licence is the essential thing to verify, because it shows that the platform respects clear requirements. Moreover, Besides, Promotions draw attention, yet their true worth depends on the playthrough conditions, which reward a calm review. Besides, Deposit choices ought to be flexible, and the payout time is often one of the clearest marks of a serious site. Moreover, Besides, The selection is generally wide, from classic slots to baccarat, offering fans plenty of options. Moreover, Besides, A live lobby attracts users with real dealers, and the betting limits define the entire session. Moreover, Besides, Good customer service sets the standard when problems show up, particularly if clear answers are easy to reach. Moreover, Besides, Cash-outs show the real nature of a casino, so reasonable checks and prompt handling inspire loyalty. Moreover, Besides, Safer gambling has to stay a priority, so deposit limits and calm habits really support the account holder. Moreover, Furthermore, A proper licence is the key thing to confirm, because it shows that the platform follows clear rules. Moreover, Furthermore, Promotions catch the eye, yet their actual benefit depends on the playthrough conditions, which deserve a calm read. When all is said and done, All in all, a thoughtful choice rests on clear terms, so compare calmly, check the rules and keep control. Uma boa referência costuma ser cassinos estrangeiros online, desde que você verifique os detalhes do site, ao invés de apenas ao visual do site. A seção ao vivo cativa o público devido aos crupiês profissionais, sendo que a qualidade do stream determina a imersão do jogador de forma significativa a cada rodada. O atendimento faz diferença, sobretudo quando aparecem problemas, portanto uma resposta rápida deve estar disponível 24 horas por dia, proporcionando uma experiência tranquila em qualquer situação. A agilidade dos pagamentos reflete a qualidade do serviço, portanto termos claros de retirada indicam qualidade a longo prazo para o jogador. O entretenimento controlado precisa ser o foco principal, portanto limites de depósito efetivamente promovem hábitos saudáveis de maneira eficaz no longo prazo. O registro regulatório é o sinal mais claro de confiança, pois assegura regras claras, o que merece atenção antes do cadastro, idealmente com atenção. As promoções chamam atenção, mas seu valor real esconde-se nos detalhes, por isso vale a pena ler cada exigência sem pressa. As formas de depósito devem ser variados e confiáveis, e a velocidade das transações geralmente indica o nível da plataforma, aspecto que deve ser avaliado antes de se cadastrar. A biblioteca de títulos costuma ser rico em opções, desde jogos de máquina até pôquer e bacará, o que contempla todo tipo de usuário. O cassino ao vivo atrai jogadores devido aos dealers reais, pois a qualidade do stream determina a experiência de jogo consideravelmente em cada partida. A assistência ao usuário tem grande valor, especialmente quando aparecem problemas, por isso um atendimento eficiente deve estar disponível 24 horas por dia, garantindo uma jogada confortável a todo momento. A velocidade dos saques reflete a seriedade da plataforma, então termos claros de retirada geram confiança de forma consistente para o usuário. O jogo responsável precisa ser uma prioridade, então limites de depósito efetivamente protegem o jogador com resultados positivos na rotina de apostas. O registro regulatório representa o sinal mais claro de confiança, pois confirma a fiscalização, o que traz tranquilidade logo no início, preferencialmente sem pressa. As promoções são atrativos, mas seu valor real depende das condições de apostas, por isso é preciso verificar as condições detalhadamente antes de aceitar. Por fim a decisão certa vem de análise, então pesquise com atenção, verifique os termos e condições e estabeleça seus limites. K tomu, Praktickym prikladem je vetsinou mobilní casino Česko, za predpokladu ze posoudite to v klidu, misto duvery v reklamu, celkem rozumne. Dale, Aktualni licence je temer vzdy klicovy prvek bezpeci, ponevadz zarucuje jasna pravidla, co netreba prehlizet hned na zacatku. Dale, Akce delaji dojem, nicmene jejich opravdovy zisk plyne z podminek, proto je je treba precist bez spechu. Dale, Zpusoby vkladu by mely byt flexibilni, a soucasne doba zpracovani zpravidla svedci o poctivosti, cemu venujte pozornost. Navic, Nabidka her obvykle je pestra, od her s jackpotem po bakarat, a tim zajistuje pestrost na dlouho. Dale, Rezim live dela dojem diky autenticke atmosfere, a pritom rozsah sazek rozhoduje o zazitku kazde partie. Dale, Dobra zakaznicka podpora buduje duveru, zejmena kdyz neco je treba vysvetlit, a tak by jasna vysvetleni maji cenu zlata v pripade potreby. Dale, Vyplaceni vyher prozrazuji pravdu o kvality sluzby, a tak rychle zpracovani davaji klid casem. Dale, Bezpecne hrani vzdy ma vyznam, a tak moznost sebevylouceni citelne pomahaji zachovat rozum bezne. Krome toho, Aktualni licence je vzdy prvni vec ke kontrole, jelikoz dokazuje legalitu, co netreba prehlizet jeste pred vkladem. Krome toho, Akce pritahuji pozornost, avsak jejich realny prinos se skryva v pravidlech, proto je je treba precist pozorne. Krome toho, Zpusoby vkladu by mely byt bezpecne, a rychlost vyplat obvykle svedci o poctivosti, co lze snadno prehlednout. Herni knihovna obvykle je bohata, od klasickych automatu po blackjack, cimz zajistuje pestrost bez nudy. Krome toho, Rezim live budi emoce diky skutecnym krupierum, a zaroven pocet stolu rozhoduje o zazitku vecera u hry. Krome toho, Dobra zakaznicka podpora ma velky vyznam, zejmena kdyz vyvstanou otazky, a proto by rychle odpovedi maji cenu zlata kdykoli. Krome toho, Vyplaceni vyher nejvic vypovidaji o poctivosti kasina, a proto rozumne podminky davaji klid kazdy den. Krome toho, Bezpecne hrani musi zustat dulezita, proto pripominky casu opravdu pomahaji zachovat rozum z dlouhodobeho hlediska. Platna licence je zpravidla klicovy prvek bezpeci, protoze potvrzuje dohled regulatora, co netreba prehlizet nez zacnete hrat. Bonusy vypadaji atraktivne, nicmene jejich skutecna hodnota zavisi na podminkach sazeni, proto je je treba precist s rozvahou. Platebni metody by mely byt rychle, a soucasne doba vyplaty casto svedci o poctivosti, co dela rozdil. Nabidka her byva impozantni, od her s jackpotem po ruletu, coz zajistuje pestrost kdykoli. Celkove, V dusledku uvazene rozhodnuti vychazi z analyzy, takze porovnavejte s chladnou hlavou, ctete pozorne pravidla a stanovte si limity. 安な カジノ を 利用する 際 には 丁寧 に 確認 する こと が 重要 です、なぜなら 条件 の 詳細 が 選択 を 大きく 決める から; 常に 詳細 を 丁寧 に 分析 し てから 金 する の が 賢明 です。 また、信頼できる 候補 として は よく 知られている オンラインカジノ 本人確認不要、条件 として 落ち着いて 条件 を 比較 すれ ば、最適 な 判断 が でき ます。 また、なお、その他にも、各種 キャンペーン は 目を 引き ます、ただし 実際 の 価値 は 条件 の 中 に あります。そのため 重 に 詳細 を 確かめ てから 受け取る こと を お勧め します。 また、決済 オプション は 多様 で 安 で ある べき です。取引 の 完了 スピード は 多く の 場合 運営 の 姿勢 を 表します。これ は プレイ 開始 前 に 確認 する 価値 が ある 重要 な 点 です。 その上、さらに、コンテンツ の 実度 は 一般 的 に 非常 に 豊富 で 多様 です。人気 の スロット から ルーレット や ブラックジャック まで、異なる 好み の 利用 に 対応 して います。 加えて、なお、ライブ カジノ は ライブ 信 の おかげ で 多く の プレイヤー を 了 します。映像 の スムーズさ が 没感 を 大きく 左右 します。 また、ユーザー サポート は 特 に 助け が 要 な とき に 大きな 差 を 生み ます。効率 的 な サポート が 要 な とき に 利用 できる こと が 重要 です。 加えて、なお、出金 の 速さ は 運営 の 姿勢 を 最も よく 示します。わかりやすい 取引 条件 が 長期 的 な 信頼 を 築き ます。 なお、さらに、コントロール された 娯楽 は 優 事 で ある べき です。支出 管理 機能 の 利用 が バランス の とれた 生活 を 促し 長期 的 に 役立ち ます。 加えて、また、なお、正規 の ライセンス は 通常 最も 明確 な 信頼 の 証 で あり、それ は 規制 当局 の 監督 を 確認 する から。これ は 初回 金 前 に 丁寧 に 確認 すべき 大切 な 事 です。 また、さらに、特 の 数 は 目を 引き ます、しかし 本当 の メリット は 条件 の 中 に あります。そのため じっくり と 条件 を 確認 し てから 判断 する の が 賢明 です。 その上、その他にも、 出金 方法 は 便利 で 信頼できる べき です。取引 の 完了 スピード は 多く の 場合 カジノ の レベル を 示します。これ は 登録 前 に チェック しておく べき ポイント です。 加えて、また、なお、コンテンツ の 実度 は 通常 実 しており 選択肢 が 豊富 です。人気 の スロット から ルーレット や ブラックジャック まで、多様 な ニーズ の ユーザー に 合わせて います。 最終的 に は 最適 な 判断 は 事実 に 基づく もの です。そのため 重 に 評価 し、条件 を 検証 し、コントロール を 保ち ながら 楽しむ こと が 大切 です。 Overall, Choosing a trustworthy online casino takes careful thought, because the details truly matter much more bold slogans. Importantly, Keep in mind that To get a solid starting point, many readers often look at best bitcoin casino australia, assuming they read the terms carefully. Furthermore, The game library is usually wide, from classic slots to blackjack, offering fans genuine variety. Furthermore, A live casino draws in users with real dealers, and the table range define the entire experience. Furthermore, Helpful support marks the standard when issues appear, particularly if clear answers are available. Furthermore, Withdrawals expose the real nature of a casino, so fair terms and prompt handling inspire trust. Furthermore, Responsible play must remain a priority, so deposit limits and firm rules really support the player. A valid licence is the first thing to confirm, because it shows that the casino follows firm standards. Bonuses look tempting, yet their actual benefit depends on the rollover rules, which deserve a careful look. Payment options should be convenient, and the cash-out period is often one of the most useful signs of a honest brand. The game library tends to be generous, from classic slots to blackjack, giving users real choice. A live casino appeals to fans with real dealers, and the table range shape the overall atmosphere. Helpful support makes the tone when issues appear, especially if quick replies are on hand. Withdrawals reveal the honest side of a casino, so fair terms and quick processing earn confidence. Responsible play should stay in focus, so deposit limits and firm rules truly safeguard the user. Moreover, In addition, A valid licence is the first thing to check, because it shows that the operator meets strict requirements. Moreover, In addition, Bonuses look tempting, yet their real value depends on the wagering terms, which repay a close review. Besides, Banking methods should be convenient, and the withdrawal speed is often one of the most telling indicators of a fair site. Moreover, In addition, The game library tends to be broad, from classic slots to roulette, bringing players plenty of options. Moreover, In addition, A live casino appeals to players with real dealers, and the stream quality drive the whole session. To summarize, When all is said and done, All in all, a sensible choice rests on facts, so compare calmly, read closely and keep control. Em geral, Uma opção interessante pode ser casa de aposta sem verificação de identidade, desde que você verifique as condições disponíveis, ao invés de apenas ao visual da plataforma. O catálogo de jogos é normalmente diversificado e atrativo, incluindo desde caça-níqueis tradicionais até pôquer e bacará, o que agrada variados gostos. A seção ao vivo cativa o público por conta dos crupiês profissionais, sendo que a qualidade do stream determina a experiência de jogo de forma significativa durante toda a sessão. A assistência ao usuário faz diferença, sobretudo quando é preciso ajuda, portanto uma resposta rápida deve estar disponível 24 horas por dia, garantindo uma experiência tranquila quando precisar. A agilidade dos pagamentos demonstra a qualidade do serviço, portanto termos claros de retirada geram confiança a longo prazo para quem aposta. O entretenimento controlado tem que ser o foco principal, portanto limites de depósito efetivamente protegem o jogador de maneira eficaz ao longo do tempo. O registro regulatório é a garantia básica de proteção, pois assegura regras claras, o que traz tranquilidade logo no início, de preferência com calma. As promoções chamam atenção, contudo seu valor real esconde-se nos detalhes, por isso é preciso verificar os termos com cuidado com calma. As formas de depósito devem ser ágeis e protegidos, e a velocidade das transações geralmente revela a qualidade do serviço, fator que merece atenção antes de depositar. A biblioteca de títulos costuma ser diversificado e atrativo, desde jogos de máquina até roleta e blackjack, isso agrada diferentes perfis de jogadores. O cassino ao vivo atrai jogadores por conta dos dealers reais, pois a qualidade do stream define a imersão do jogador de forma significativa a cada rodada. O suporte ao cliente tem grande valor, especialmente quando é preciso ajuda, por isso um atendimento eficiente deve estar disponível a qualquer hora, proporcionando uma experiência tranquila em qualquer situação. A velocidade dos saques demonstra a seriedade da plataforma, então termos claros de saque indicam qualidade a longo prazo para o jogador. O jogo responsável tem que ser uma prioridade, então limites de depósito realmente promovem hábitos saudáveis de maneira eficaz no longo prazo. O registro regulatório representa a garantia básica de proteção, pois confirma a fiscalização, o que traz tranquilidade antes do cadastro, idealmente com atenção. Dito isso, Em resumo uma seleção acertada vem de análise, então avalie com cuidado, verifique os termos e condições e mantenha o controle. Merita attenzione di regola casino online stranieri, solo quando verifichi la licenza, invece di credere alla pubblicita, con la dovuta attenzione, per valutare ogni aspetto. Il gioco responsabile deve restare importante, percio gli avvisi sul tempo danno un senso di controllo in ogni momento, senza perdere equilibrio prima di decidere. Una licenza valida e quasi sempre l elemento chiave di sicurezza, perche conferma la vigilanza, cosa da non ignorare prima di registrarti, con attenzione prima della scelta. I bonus fanno impressione, ma il loro guadagno effettivo dipende dal rollover, percio conviene leggerli con calma, in modo chiaro prima della scelta. I metodi di pagamento dovrebbero essere flessibili, e la durata del processo spesso riflette l onesta, cosa da verificare, in modo chiaro prima della scelta. Inoltre, La libreria di giochi di solito e variata, da giochi con jackpot fino a roulette, il che assicura varieta ogni giorno, con valutazioni attente prima della scelta. Il casino dal vivo fa impressione grazie a un atmosfera autentica, e la qualita dello stream decide l esperienza dell intera sessione, in modo evidente prima della scelta. Un assistenza cortese crea fiducia, soprattutto quando qualcosa va chiarito, percio la chat dal vivo valgono oro in ogni momento, con risposte precise prima della scelta. I prelievi rivelano la verita su la qualita del servizio, percio limiti chiari danno tranquillita a lungo termine, con effetti visibili prima della scelta. Un approccio prudente conta sempre, percio i limiti di deposito aiutano a mantenere la lucidita ogni giorno, con attenzione costante prima della scelta. Una licenza affidabile e di solito l elemento chiave di sicurezza, perche garantisce regole chiare, cio che da tranquillita prima di registrarti, con attenzione durante il confronto. I premi iniziali sono allettanti, ma il loro guadagno effettivo deriva dal regolamento, percio vanno verificati con calma, in modo chiaro durante il confronto. Le opzioni di incasso dovrebbero essere comodi, e la durata del processo in genere rivela l approccio dell operatore, cosa da verificare, in modo chiaro durante il confronto. La libreria di giochi si presenta ampia, da giochi con jackpot fino a baccara, il che accontenta giocatori diversi ogni giorno, con valutazioni attente durante il confronto. In breve una decisione consapevole poggia sui numeri, quindi non avere fretta, leggi con attenzione le regole e usa il buon senso, in qualsiasi momento.
 

13 Feb FDA Approves Eisai’s LENVIMA (lenvatinib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Posted at 15:33h in News by
0 Likes
– New Therapy Demonstrated a Dramatic Improvement in Progression-Free Survival and a Statistically Significant Overall Response Rate in Some Patients with RAI-Refractory Differentiated Thyroid Cancer
– File Submission and Approval Based on Data from Phase 3 SELECT Study Published in New England Journal of Medicine on February 12, 2015
– Approval Granted Two Months Ahead of FDA Priority Review PDUFA Date
 

WOODCLIFF LAKE, N.J., Feb. 13, 2015 /PRNewswire/ — Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the company’s receptor tyrosine kinase inhibitor LENVIMA™ (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). LENVIMA was approved following a priority review by the FDA, which is designated for drugs the FDA believes have the potential to provide a significant improvement in the treatment of a serious condition. LENVIMA demonstrated a statistically significant progression-free survival (PFS) prolongation and response rate in patients with progressive, differentiated thyroid cancer who had become refractory to radioactive iodine (RAI) therapy.

Experience the interactive Multimedia News Release here  http://www.multivu.com/players/English/7364531-eisai-lenvima-fda-approval/

“In the pivotal Phase 3 SELECT clinical trial, recently published in the New England Journal of Medicine, treatment with LENVIMA resulted in a highly statistically significant improvement in progression-free survival and a high overall response rate in patients with locally recurrent or metastatic, progressive, RAI-refractory DTC,” said Lori J. Wirth, M.D., study investigator and medical director of the Center for Head and Neck Cancers at the Massachusetts General Hospital. “The thyroid cancer community welcomes an agent that offers a significant, effective option for the treatment of differentiated thyroid cancer in patients who have progressed after becoming refractory to RAI therapy.”

“The incidence of thyroid cancer has been increasing globally over the last 50 years and for patients with thyroid cancer that progresses following surgery and radioactive iodine treatment, the prognosis is often poor,” said Gary Bloom, Executive Director of ThyCa: Thyroid Cancer Survivors’ Association, Inc. “We are excited about the approval of LENVIMA, which may help address an unmet need as there are limited treatment options for patients with this type of thyroid cancer.”

In the Phase 3 SELECT trial, which included 392 patients, LENVIMA demonstrated a highly statistically significant improvement in PFS in patients with RAI-R DTC compared with placebo. The median PFS, or delay in the length of time during and after treatment in which the disease did not worsen, with LENVIMA and placebo was 18.3 months and 3.6 months, respectively (HR 0.21; 95% CI: 0.16-0.28; p<0.001). In addition, an overall response rate, the sum of partial and complete response rates, of 65% was seen in patients treated with LENVIMA versus 2% with placebo, which included a complete response achieved in 2% of patients treated with LENVIMA versus 0% with placebo. Based on RECIST v1.1 criteria, a partial response is defined as a minimum 30% decrease in the sum of diameters of target lesions and a complete response is defined as a complete disappearance of tumors.

Serious risks seen in patients in the Phase 3 SELECT clinical trial were hypertension, cardiac dysfunction, arterial thromboembolic events, hepatotoxicity, proteinuria, renal failure and impairment, gastrointestinal perforation and fistula formation, QT interval prolongation, hypocalcemia, reversible posterior leukoencephalopathy syndrome, hemorrhagic events,  impairment of exogenous thyroid suppression and embryofetal toxicity. The most common adverse reactions observed in greater than or equal to 30% of LENVIMA-treated patients, in order of decreasing frequency, were: hypertension, fatigue, diarrhea, arthralgia/myalgia, decreased appetite, weight decreased, nausea, stomatitis, headache, vomiting, proteinuria, palmar-plantar erythrodysesthesia (PPE) syndrome, abdominal pain, and dysphonia. The most common serious adverse reactions (at least 2%) were pneumonia (4%), hypertension (3%), and dehydration (3%).

It is important for doctors to know that when treating with LENVIMA, they may modify the dose as needed according to the recommendations provided in the prescribing information. Management of some adverse reactions may require the dose of LENVIMA to be withheld, reduced or discontinued. Upon resolution/improvement of an adverse reaction, treatment may be resumed at a reduced dose as suggested in the prescribing information. In the clinical trial, adverse events led to dose reductions in 68% of patients who received LENVIMA and 5% of patients who received placebo. Some patients will need to discontinue treatment for serious adverse reactions. In the trial, 18% of patients treated with LENVIMA and 5% who received placebo discontinued treatment. The most common adverse reactions (at least 10%) that resulted in dose reductions of LENVIMA were hypertension (13%), proteinuria (11%), decreased appetite (10%), and diarrhea (10%). The most common adverse reactions (at least 1%) resulting in discontinuation of LENVIMA were hypertension (1%) and asthenia (1%).

“We are excited that LENVIMA was approved today by the FDA following the priority review designation received in October and look forward to offering this new treatment option to patients with progressive, RAI-refractory DTC,” said Takashi Owa, Ph.D., Chief Innovation Officer at Eisai. “Eisai is committed to innovative research and product creation with the goal of helping patients with cancer.”

Eisai is committed to ensuring patients have access to medicines from which they may benefit and is dedicated to working to ensure that our products are available to those who need them. Once LENVIMA is available, Eisai will provide reimbursement support programs for eligible patients.

LENVIMA™ (lenvatinib) will be available to order in the near future through specialty pharmacies Biologics, Inc. and Accredo.

About the LENVIMA™ (lenvatinib) Pivotal Clinical Trial
The SELECT (Study of E7080 LEnvatinib in Differentiated Cancer of the Thyroid) study was a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to compare the PFS of patients with locally recurrent or metastatic RAI-R DTC and radiographic evidence of disease progression within 12 months prior to randomization, treated with LENVIMA (24 mg) once daily or placebo. Other outcome measures of the study included overall response rate (ORR), overall survival (OS) and safety. The study enrolled 392 patients stratified by geographic region, prior VEGF/VEGFR targeted therapy and age and randomized at a ratio of 2:1 to receive treatment with either LENVIMA 24 mg/day (administered orally, once a day) or placebo. The SELECT study was conducted by Eisai in collaboration with the SFJ Pharmaceuticals Group.

The full results of this study were presented at the 2014 ASCO Annual Meeting and recently published in the New England Journal of Medicine.

About Thyroid Cancer
Thyroid cancer refers to cancer that forms in the tissues of the thyroid gland, located at the base of the throat near the trachea. It is more common in women than in men and most are in their 40s or 50s at the time of diagnosis. Thyroid cancer is the most common endocrine malignancy and global figures show that its incidence has increased significantly over the last 50 years.

The most common types of thyroid cancer, papillary and follicular (including Hürthle cell), are classified as differentiated thyroid cancer (DTC) and account for approximately 90% of all cases. While most DTC patients are curable with surgery and radioactive iodine treatment, the prognosis for those patients whose cancers persist or recur is poor. There are limited treatment options for this radioactive iodine-refractory form of thyroid cancer.

About LENVIMA™ (lenvatinib)
LENVIMA, discovered and developed by Eisai, is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. It is currently under investigation in hepatocellular, renal cell carcinoma, endometrial, anaplastic thyroid cancer, non-small cell lung cancer and other solid tumor types. LENVIMA was granted Priority Review designation by the FDA in October 2014. Eisai was granted Orphan Drug Designation (ODD) for lenvatinib in various types of thyroid cancer in the United States, Japan, and Europe.

LENVIMA™ (lenvatinib) Important Safety Information

Warnings and Precautions

Hypertension was reported in 73% of LENVIMA-treated patients (of which 44% were > Grade 3) and 16% of patients in the placebo group. Control blood pressure prior to treatment and monitor blood pressure after 1 week, then every 2 weeks for the first 2 months, and then at least monthly during treatment.  Withhold LENVIMA for Grade 3 hypertension; resume at a reduced dose when hypertension is controlled at < Grade 2. Discontinue LENVIMA for life-threatening hypertension.

Cardiac dysfunction was reported in 7% of LENVIMA-treated patients (2% Grade 3 or greater). Monitor patients for clinical symptoms or signs of cardiac decompensation. Withhold LENVIMA for development of Grade 3 cardiac dysfunction until improved to Grade 0 or 1 or baseline. Resume at a reduced dose or discontinue LENVIMA depending on the severity and persistence of cardiac dysfunction. Discontinue LENVIMA for Grade 4 cardiac dysfunction.

Arterial thromboembolic events were reported in 5% of LENVIMA-treated patients; events of Grade 3 or greater were 3%. Discontinue LENVIMA following an arterial thrombotic event. LENVIMA has not been studied in patients who have had an arterial thromboembolic event within the previous 6 months.

4% of LENVIMA-treated patients experienced an increase in ALT and 5% experienced an increase in AST that was Grade 3 or greater. Monitor liver function before initiation and during treatment with LENVIMA™ (lenvatinib). Withhold LENVIMA for the development of > Grade 3 liver impairment until resolved to Grade 0 to 1 or baseline. Resume at a reduced dose or discontinue LENVIMA depending on the severity and persistence of hepatotoxicity. Discontinue LENVIMA for hepatic failure.

Proteinuria was reported in 34% of LENVIMA-treated patients (of which 11% were Grade 3).  Monitor for proteinuria before initiation of, and periodically during treatment. Obtain a 24 hour urine protein if urine dipstick proteinuria >2+ is detected. Withhold LENVIMA for > 2 grams of proteinuria/24 hours and resume at a reduced dose when proteinuria is <2 gm/24 hours. Discontinue LENVIMA for nephrotic syndrome.

Events of renal impairment were reported in 14% of LENVIMA-treated patients.  Renal failure or impairment > Grade 3 was 3% in LENVIMA-treated patients. Withhold LENVIMA for development of Grade 3 or 4 renal failure/impairment until resolved to Grade 0 to 1 or baseline. Resume at a reduced dose or discontinue LENVIMA depending on the severity and persistence of renal impairment. 

Events of gastrointestinal perforation or fistula were reported in 2% of LENVIMA-treated patients.  Discontinue LENVIMA in patients who develop gastrointestinal perforation or life-threatening fistula.

QT/QTc interval prolongation was reported in 9% of LENVIMA-treated patients (2% Grade 3 or greater).  Monitor ECG in patients with congenital long QT syndrome, CHF, bradyarrhythmias, or patients taking drugs known to prolong the QT interval. Monitor and correct electrolyte abnormalities in all patients.  Withhold LENVIMA for the development of >Grade 3 QT interval prolongation. Resume LENVIMA at a reduced dose when QT prolongation resolves to Grade 0 or 1 or baseline.

Hypocalcemia > Grade 3 was reported in 9 % of LENVIMA-treated patients. Monitor blood calcium levels at least monthly and replace calcium as necessary during LENVIMA treatment. Interrupt and adjust LENVIMA dosing as necessary depending on severity, presence of ECG changes, and persistence of hypocalcemia.

Reversible posterior leukoencephalopathy syndrome (RPLS) was reported in 3 patients across clinical studies in which 1108 patients received LENVIMA. Confirm the diagnosis of RPLS with MRI.  Withhold LENMIVA for RPLS until fully resolved. Resume at a reduced dose or discontinue LENVIMA depending on the severity and persistence of neurologic symptoms.

Hemorrhagic events occurred in 35% of LENVIMA-treated patients and in 18% of the placebo group.  The incidence of Grade 3-5 hemorrhage was similar between arms at 2% and 3%, respectively.  The most frequently reported hemorrhagic event was epistaxis (11% Grade 1 and 1% Grade 2). Discontinuation due to hemorrhagic events occurred in 1% of LENVIMA-treated patients. There was one case of fatal intracranial hemorrhage among 16 patients who received LENVIMA and had CNS metastases at baseline. Withhold LENVIMA for the development of Grade 3 hemorrhage until resolved to Grade 0 to 1.  Resume at a reduced dose or discontinue LENVIMA depending on the severity and persistence of hemorrhage. Discontinue LENVIMA in patients who experience Grade 4 hemorrhage.

LENVIMA impairs exogenous thyroid suppression. Elevation of TSH level above 0.5 mU/L was observed post baseline in 57% of LENVIMA-treated patients. Monitor TSH levels monthly and adjust thyroid replacement medication as needed.

LENVIMA can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with LENVIMA and for at least 2 weeks following completion of therapy.

Advise women not to breastfeed during treatment with LENVIMA.

Adverse Reactions

The most common adverse reactions observed in LENVIMA-treated patients vs. placebo treated patients respectively were hypertension (73% vs 16%), fatigue (67% vs 35%), diarrhea (67% vs 17%), arthralgia/myalgia (62% vs 28%), decreased appetite (54% vs 18%), weight decreased (51% vs 15%), nausea (47% vs 25%), stomatitis (41% vs 8%), headache (38% vs 11%), vomiting (36% vs 15%), proteinuria (34% vs 3%), palmar-plantar erythrodysesthesia syndrome (32% vs 1%), abdominal pain (31% vs 11%), and dysphonia (31% vs 5%).

For more information about LENVIMA, click here for the full Product Information or visit www.LENVIMA.com.

LENVIMA™ (lenvatinib) Indication
LENVIMA™ (lenvatinib) is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine refractory differentiated thyroid cancer (DTC).

About Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer’s disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com/US.

Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina. Eisai’s global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.

About the SFJ Pharmaceuticals Group
The SFJ Pharmaceuticals Group, which includes SFJ Pharma Ltd., is a global drug development company, which provides a unique co-development partnering model for some of the world’s top pharmaceutical and biotechnology companies. SFJ uses its financial strength and core team of pharmaceutical development experts to provide highly customized partnering models in which SFJ provides the funding and clinical development supervision, necessary to obtain regulatory approval for some of the most promising drug development programs of pharmaceutical and biotechnology companies.

 

 

                        Media Inquiries

                        Laurie Landau

                        Eisai Inc.

                        (201) 746-2510

                                    

 

        Investor Inquiries

        Alex Scott

        Eisai Inc.

        (201) 746-2177

 

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/fda-approves-eisais-lenvima-lenvatinib-for-the-treatment-of-patients-with-locally-recurrent-or-metastatic-progressive-radioactive-iodine-refractory-differentiated-thyroid-cancer-300036074.html

SOURCE Eisai Inc.

TYPEPress Release

DATE RELEASEDFebruary 13, 2015

 
SUBSCRIBE TO OUR NEWS